Status:
COMPLETED
Determination of Blood Tumor Cells
Lead Sponsor:
University of Zurich
Conditions:
Leukemia, Lymphocytic, Chronic, B-Cell
Abnormalities Cell Epithelial
Eligibility:
All Genders
18+ years
Brief Summary
Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .
Detailed Description
Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (E...
Eligibility Criteria
Inclusion
- Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)
Exclusion
- Inability to understand the language of the center (German)
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT04290923
Start Date
October 1 2017
End Date
December 30 2022
Last Update
January 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland, 8091